Vallon Pharmaceuticals (VLON) Financials

$8.59

$-351.42 (-97.62%)

As on 24-Apr-2023 09:30EDT

Market cap

$5 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	--	--	--	0.10	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	0.10	--	--
Operating Expenses	6.89	6.93	9.26	4.89	3.15	4.31
Operating Profit (EBIT)	-6.68	-6.93	-9.26	-4.79	-3.15	-4.31
Other Income	--	--	--	--	--	--
Profit before Tax	-6.79	-7.02	-9.30	-4.82	-3.46	-4.31
Provision for Tax	0.16	0.19	0.09	0.03	0.42	--
Profit after Tax (Net Income)	-6.94	-7.22	-9.39	-4.86	-3.89	-4.31
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-2.81	--	-9.30	-4.82	-3.46	-4.31

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	0.03	2.34	5.82	-1.45	3.21	0.15
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	1.54	0.98	0.07	0.18	0.25	--
Current Liabilities	0.53	1.81	2.45	2.23	0.81	0.49
Total Liabilities	2.63	4.15	8.34	0.96	4.28	0.64

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	--	--	0.21	0.28	0.35	0.00
Current Assets	1.67	4.15	8.13	0.67	3.92	0.64
Total Assets	3.76	4.15	8.34	0.96	4.28	0.64
Total Debt*	--	--	0.17	0.34	0.34	--
Net Current Assets	--	2.34	5.68	-1.55	3.11	0.15

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-7.14	-8.31	-3.71	-2.88	-2.37
Cash Flow from Investing Activities	--	--	-3.84	0.00	0.00	0.00
Cash from Financing Activities	--	3.43	15.75	0.00	6.09	2.99
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-0.48	-0.71	-1.38	-0.85	-0.58	--
Cash EPS ($)	--	-0.69	-1.37	-0.84	-0.57	--
Adjusted Book Value ($)	--	0.23	0.85	--	0.48	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.70	-1.22	-0.65	-0.43	--
Free Cash Flow per Share ($)	--	-0.70	-1.22	-0.65	-0.43	--

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	-173.27	-385.79	-398.72	-209.76	--
ROE (%)	-397.82	-176.86	-430.43	-551.88	-230.94	--
ROA (%)	-113.39	-115.58	-202.20	-185.67	-158.20	--
EBIT Margin (%)	--	--	--	-4,788.00	--	--
Net Margin (%)	--	--	--	-4,856.00	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	--	-1.00	--	--	--
EBIT Growth (%)	28.16	25.18	-93.38	-51.79	26.86	--
Net Profit Growth (%)	25.38	23.17	-93.41	-24.91	9.86	--
EPS Growth (%)	64.87	0.48	-0.62	-0.48	--	--
Book Value Growth (%)	-99.99	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	-0.41	-4.34	--	--	--
Price / Book Value	0.84	1.26	7.00	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.53	0.13	-3.66	--	--	--
Close Price ($)	10.86	8.70	179.40	--	--	--
High Price ($)	80.40	252.00	310.80	--	--	--
Low Price ($)	6.15	6.15	108.30	--	--	--
Market Cap ($ Cr)	5.39	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	--	0.03	-0.23	0.11	--
Short term debt to equity ratio	--	--	0.02	-0.10	0.03	--
Current Ratio	3.15	2.29	3.32	0.30	4.86	1.31
Quick Ratio	3.15	--	--	--	--	--
Interest Coverage	-149.78	-266.46	-578.69	-140.82	--	--

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	0.04	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.